OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGNFree Report) in a research note released on Friday morning. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Price Performance

OPGN stock opened at $0.32 on Friday. The stock has a market capitalization of $3.20 million, a PE ratio of -0.05 and a beta of -0.90. The company’s 50-day moving average is $0.39 and its 200-day moving average is $0.42. OpGen has a 1 year low of $0.17 and a 1 year high of $3.84.

OpGen (NASDAQ:OPGNGet Free Report) last released its quarterly earnings data on Tuesday, November 14th. The medical research company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.90 million. OpGen had a negative return on equity of 316.30% and a negative net margin of 852.18%. On average, analysts anticipate that OpGen will post -2.02 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OpGen

A number of institutional investors and hedge funds have recently made changes to their positions in OPGN. Vanguard Group Inc. boosted its position in shares of OpGen by 39.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock worth $537,000 after purchasing an additional 534,960 shares in the last quarter. HRT Financial LP bought a new position in OpGen in the 4th quarter valued at about $26,000. Citadel Advisors LLC lifted its position in OpGen by 571.0% in the 3rd quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 85,754 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in OpGen in the 1st quarter valued at about $49,000. Institutional investors own 13.07% of the company’s stock.

About OpGen

(Get Free Report)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Read More

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.